Biotech News
Related news
ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
ANTXAN2 Therapeutics2026-05-21 11:00 EST
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
AVIRAtea2026-05-13 11:00 EST
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
ASMBAssembly Biosciences2026-09-10 20:15 EST
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
ASMBAssembly Biosciences2026-05-11 12:00 EST
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
ANTXAN2 Therapeutics2026-02-17 12:00 EST
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
SPROSpero Therapeutics2026-09-02 21:01 EST
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
IMNNImunon2026-07-23 13:25 EST
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
Atea
Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...
Recent company news
AVIRAtea2026-09-08 11:00 EST
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
AVIRAtea2026-08-12 20:05 EST
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Stock data
- Close
- 5.26 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States